ReviewJournal of translational medicine2026
Functional regulation of GlycoRNA and progress in malignant tumors.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGlycans form unique GlycoRNAs through covalent modification of RNA molecules. GlycoRNAs serve as key components in intercellular communication. Early diagnosis and treatment of malignant tumors have always been the focus of cancer research, and the emergence of GlycoRNA has brought new opportunities to this field. MAIN BODY: With breakthroughs in detection technologies, the structure and function of GlycoRNA are being gradually revealed. Here we describe the multiple biological functions of GlycoRNA and discuss the newly discovered GlycoRNA present in the exosomal lumen. This article primarily focuses on the structure and functional regulation of GlycoRNA, as well as detection technologies, to illustrate its potential in tumor diagnosis and treatment.
conclusionOur aim is to provide new perspectives for GlycoRNA biology research and promote its applications in malignant tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.